| Literature DB >> 29769727 |
Marlies Meisel1,2, Reinhard Hinterleitner1,2, Alain Pacis3,4, Li Chen1,2, Zachary M Earley1,2, Toufic Mayassi1,2, Joseph F Pierre1,5, Jordan D Ernest1,2, Heather J Galipeau6, Nikolaus Thuille7, Romain Bouziat1,2, Manuel Buscarlet8, Daina L Ringus1, Yitang Wang9, Ye Li9, Vu Dinh1,2, Sangman M Kim1,2, Benjamin D McDonald1,9, Matthew A Zurenski1,2, Mark W Musch1, Glaucia C Furtado10, Sergio A Lira10, Gottfried Baier7, Eugene B Chang1, A Murat Eren1,11, Christopher R Weber9, Lambert Busque8,12, Lucy A Godley1,13, Elena F Verdú6, Luis B Barreiro3,14, Bana Jabri15,16,17.
Abstract
Somatic mutations in tet methylcytosine dioxygenase 2 (TET2), which encodes an epigenetic modifier enzyme, drive the development of haematopoietic malignancies1-7. In both humans and mice, TET2 deficiency leads to increased self-renewal of haematopoietic stem cells with a net developmental bias towards the myeloid lineage1,4,8,9. However, pre-leukaemic myeloproliferation (PMP) occurs in only a fraction of Tet2-/- mice8,9 and humans with TET2 mutations1,3,5-7, suggesting that extrinsic non-cell-autonomous factors are required for disease onset. Here we show that bacterial translocation and increased interleukin-6 production, resulting from dysfunction of the small-intestinal barrier, are critical for the development of PMP in mice that lack Tet2 expression in haematopoietic cells. Furthermore, in symptom-free Tet2-/- mice, PMP can be induced by disrupting intestinal barrier integrity, or in response to systemic bacterial stimuli such as the toll-like receptor 2 agonist. PMP was reversed by antibiotic treatment and failed to develop in germ-free Tet2-/- mice, which illustrates the importance of microbial signals in the development of this condition. Our findings demonstrate the requirement for microbial-dependent inflammation in the development of PMP and provide a mechanistic basis for the variation in PMP penetrance observed in Tet2-/- mice. This study will prompt new lines of investigation that may profoundly affect the prevention and management of haematopoietic malignancies.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29769727 PMCID: PMC6238954 DOI: 10.1038/s41586-018-0125-z
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962